Light Chain Deposition Disease with Renal Involvement: Clinical Characteristics and Prognostic Factors

American Journal of Kidney Diseases

Volumn 42, Issue 6, 2003, Pages 1154-1163

  Pozzi, Claudio ^a   D'Amico, Marco ^b   Fogazzi, Giovanni B ^b   Curioni, Simona ^b   Ferrario, Franco ^b   Pasquali, Sonia ^b   Quattrocchio, Giacomo ^b   Rollino, Cristiana ^b   Segagni, Siro ^b   Locatelli, Francesco ^b  

^a A MANZONI HOSPITAL   (Italy)

^b NONE

Author keywords

Autologous stem cell transplantation; Chemotherapy; Diagnosis; Doxorubicin; Light chain deposition disease (LCDD); Renal insufficiency; Survival

Indexed keywords

CREATININE; IMMUNOGLOBULIN LIGHT CHAIN; PROTEIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULOPATHY; HISTOLOGY; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; INCIDENCE; KIDNEY BIOPSY; LIGHT CHAIN DEPOSITION DISEASE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROGNOSIS; PROTEINURIA; SURVIVAL; SYSTEMIC DISEASE; UREMIA;

EID: 10744228129     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.08.040     Document Type: Article

References (25)

1. Randall RE, Williams WC, Mullinax F, et al: Manifestations of systemic light chain deposition. Am J Med 69:703-710, 1976
2. Pozzi C, Locatelli F: The patient with insidious chronic renal failure and the patient with the nephrotic syndrome - Two manifestations of a protean and not so rare disease. Nephrol Dial Transplant 1:1876-1880, 1996
3. Pozzi C, Fogazzi GB, Banfi G, et al: Renal disease and patient survival in light chain deposition disease. Clin Nephrol 43:281-287, 1995
4. Heilman RL, Velosa JA, Holley KE, et al: Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 20:34-41, 1992
5. Lin J, Markowitz GS, Valeri AM, et al: Renal monoclonal immunoglobulin deposition disease: The disease spectrum. J Am Soc Nephrol 12:1482-1492, 2001
6. Montseny JJ, Kleinknecht D, Meyrier A, et al: Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 13:1438-1445, 1998
7. Durie BGM: Plasma cell disorders: Recent advances in the biology and treatment, in Hoffbrand AV (ed): Recent Advances in Aematology, Vol 5. New York, NY, Churchill Livingston, 1989, pp 305-327
8. Ganeval D, Noël LH, Preud'homme JL, et al: Light-chain deposition disease: Its relation with AL-type amyloidosis. Kidney Int 26:1-9, 1984
9. Denoroy L, Deret S, Aucouturier P: Overrepresentation of the VkIV subgroup in light chain deposition disease. Immunol Lett 42:63-66, 1994
10. Buxbaum JN, Chuba JV, Hellman GC, et al: Monoclonal immunoglobulin deposition disease: Light chain and light and heavy chain deposition disease and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 112:455-464, 1990
11. Preud'homme JL, Morel-Maroger L, Brouet JC, et al: Synthesis of abnormal immunoglobulins in lymphoplasmacytic disorders with visceral light chain deposition. Am J Med 69:703-710, 1980
12. IV subgroup in the kidney and plasma cells in light chain deposition disease. J Clin Invest 87:2186-2191, 1991
13. Strom EH, Fogazzi GB, Banfi G, et al: Light chain deposition disease of the kidney. Morphological aspects in 24 patients. Virch Arch 425:271-280, 1994
14. Bangerter AR, Murphy WM: Kappa light chain nephropathy. Virch Arch 410:531-539, 1987
15. Pirani CL, Silva F, D'Agati V, et al: Renal lesions in plasma cell dyscrasias: Ultrastructural observations. Am J Kidney Dis 10:208-221, 1987
16. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P: Light chain deposition disease: A model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 12:1558-1565, 2001
17. Herrera GA, Sanders PW, Reddy BV, Hasbargen JA, Hammond WS, Brooke JD: Ultrastructural immunolabeling: A unique diagnostic tool in monoclonal light chain-related renal diseases. Ultrastruct Pathol 18:401-16, 1994
18. Gianni IL, Bellotti V, Gianni AM, et al: New drug therapy of amyloidoses: Resorption of AL-type deposits with 4′-iodo-4′deoxydoxorubicin. Blood 86:855-861, 1995
19. Merlini G, Anesi E, Garini P, et al: Treatment of AL amyloidosis with 4′-iodo-4′deoxydoxorubicin: An update. Blood 93:1112-1123, 1999
20. Gertz MA, Lacy MQ, Dispenzieri A, et al: A multicenter phase II trial of 4′-iodo-4′deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 9:24-30, 2002
21. Comenzo RL, Gertz MA: Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99:4276-4282, 2002
22. Mariette X, Clauvel JP, Brouet JC: Intensive therapy in AL amyloidosis and light-chain deposition disease. Ann Intern Med 123:553, 1995
23. Moroni G, Banfi G, Montoli A, et al: Chronic dialysis in patients with systemic amyloidosis: The experience in northern Italy. Clin Nephrol 38:81-85, 1992
24. Gertz MA, Kyle RA, O'Fallon WM: Dialysis support of patients with primary systemic amyloidosis: A study of 211 patients. Arch Intern Med 152:2245-2250, 1992
25. Ivanyi B: Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 11:986-987, 1990